BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 2, 2004
View Archived Issues
Pozen's Second Migraine Drug, MT 100, Turned Down By FDA
Pozen Inc.'s stock plummeted Tuesday on news that it received a not-approvable letter from the FDA for its migraine drug MT 100. (BioWorld Today)
Read More
$180M Stock-Swap Merger Joins Aclara With ViroLogic
Read More
SuperGen Submits First Part Of Rolling NDA For Dacogen
Read More
ARYx Raises $55M To Fund Development Of Safer Drugs
Read More
Serono Starts Phase III Trial Of Serostim In HARS Patients
Read More
Other News To Note
Read More